Teva Pharmaceutical Industries Ltd (TEVA) Stake Held by C WorldWide Group Holding A S

Teva Pharmaceutical Industries Ltd (TEVA) Stake Held by C WorldWide Group Holding A S

C WorldWide Group Holding A S maintained its position in shares of Teva Pharmaceutical Industries Ltd (NYSE:TEVA) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 273,050 shares of the company’s stock at the end of the first quarter. C WorldWide Group Holding A S’s holdings in Teva Pharmaceutical Industries were worth $8,762,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of the company. Cribstone Capital Management LLC increased its position in shares of Teva Pharmaceutical Industries by 3.3% in the first quarter. Cribstone Capital Management LLC now owns 3,141 shares of the company’s stock worth $101,000 after buying an additional 100 shares in the last quarter. Financial Architects Inc increased its position in shares of Teva Pharmaceutical Industries by 2.3% in the first quarter. Financial Architects Inc now owns 4,443 shares of the company’s stock worth $143,000 after buying an additional 100 shares in the last quarter. Advisory Services Network LLC bought a new position in shares of Teva Pharmaceutical Industries during the first quarter worth approximately $163,000. Elite Wealth Management LLC bought a new position in shares of Teva Pharmaceutical Industries during the third quarter worth approximately $166,000. Finally, CKW Financial Group bought a new position in shares of Teva Pharmaceutical Industries during the third quarter worth approximately $168,000. Institutional investors and hedge funds own 55.03% of the company’s stock.

Teva Pharmaceutical Industries Ltd (NYSE:TEVA) traded up 0.87% on Friday, hitting $31.14. 5,403,345 shares of the company’s stock were exchanged. The company’s 50-day moving average price is $32.01 and its 200-day moving average price is $35.51. The company has a market cap of $31.61 billion, a PE ratio of 444.86 and a beta of 0.58. Teva Pharmaceutical Industries Ltd has a 12-month low of $30.22 and a 12-month high of $56.44.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings data on Monday, February 13th. The company reported $1.38 earnings per share for the quarter, topping the consensus estimate of $1.36 by $0.02. The business earned $6.25 billion during the quarter, compared to the consensus estimate of $6.26 billion. Teva Pharmaceutical Industries had a net margin of 1.50% and a return on equity of 17.46%. The company’s revenue was up 33.0% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.32 EPS. Analysts forecast that Teva Pharmaceutical Industries Ltd will post $4.82 earnings per share for the current year.

A number of equities analysts have commented on TEVA shares. Citigroup Inc restated a “buy” rating and issued a $47.00 target price on shares of Teva Pharmaceutical Industries in a research note on Tuesday, February 7th. Gabelli restated a “buy” rating on shares of Teva Pharmaceutical Industries in a research note on Monday, January 9th. Cowen and Company restated a “buy” rating and issued a $50.00 target price (down from $100.00) on shares of Teva Pharmaceutical Industries in a research note on Tuesday, January 10th. Royal Bank of Canada set a $42.00 target price on shares of Teva Pharmaceutical Industries and gave the stock a “buy” rating in a research note on Monday, January 9th. Finally, Bank of America Corp upgraded shares of Teva Pharmaceutical Industries from a “neutral” rating to a “buy” rating in a research note on Tuesday, January 31st. One investment analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and fourteen have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus price target of $44.75.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Ltd (NYSE:TEVA).

Related posts

Leave a Comment